EricPadronMD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

H. Lee Moffitt Cancer Center

Overview of Dr. Padron

Dr. Eric Padron is a hematologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from University of Florida College of Medicine and has been in practice 11 years. He specializes in hematologic oncology and myeloproliferative disorder hematology-oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma.

Office
12902 Magnolia Drive
Tampa, FL 33612
Book by Phone+1(813) 669-0154

Fax+1 352-338-9879
Is this information wrong?

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2009 - 2012
University of FloridaResidency, Internal Medicine, 2006 - 2009
University of Florida College of MedicineClass of 2006

Certifications & Licensure

FL State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia Start of enrollment: 2011 Apr 06
Terminated
Phase 1
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib Start of enrollment: 2013 Feb 20
Completed
Phase 1, Phase 2
Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) Start of enrollment: 2013 Aug 29
Completed
Phase 2
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion Start of enrollment: 2019 Aug 28
Active, not recruiting
Phase 2
PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS Start of enrollment: 2019 May 20
Recruiting
Phase 1
Quality of Life Model for Older Patients With AML Start of enrollment: 2020 Jul 08
Active, not recruiting
CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML Start of enrollment: 2021 Jan 14
Active, not recruiting
Phase 1, Phase 2
Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Start of enrollment: 2021 Mar 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Lisa Nodzon, Amanda Rodriguez, Akriti G Jain, Quinto Gesiotto, Somedeb Ball, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A Sallman, Jeffrey E Lanc...> ;Annals of Hematology. 2024 Apr 18
HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Ana...
Nishan Sengupta, Dylan Supina, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Rami S Komrokji, Shyamala Navada, Eric Padron, David Sallman> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML.
Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda Deutsch, Ling Zhang, Mohammad Hussaini, Jinming Song, Seon...> ;Blood Advances. 2024 Mar 12
A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
Rajagopalan, A., Feng, Y., Gayatri, M., Ranheim, E., Klungness, T., Matson, D., Lee, M., Jung, M., Zhou, Y., Gao, X., Nadiminti, K., Yang, D., Tran, V., Padron, E., Mi...> ;The Journal of Clinical Investigation. 2023 Dec 15
1 citations
TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Ayalew Tefferi, Farah Fleti, Onyee Chan, Najla H Al Ali, Aref Al-Kali, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Mithun Shah, Devendra Hiwase, Eric Pa...> ;British Journal of Haematology. 2024 Apr 1
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities.
Nathan P Horvat, Enas F Abdallah, Zhuoer Xie, Najla Al Ali, Seongseok Yun, Alison Walker, Eric Padron, David Sallman, Onyee Chan, Jeffrey Lancet, Rami Komrokji, Andrew...> ;Annals of Hematology. 2024 Jan 1
6 citations
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Cons...
Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, Matteo Giovanni Della Porta, Rami Komrokji, Mina L Xu, Omar Abdel-Wahab, Justin Taylor, David P Steensma, Daniel ...> ;Blood Reviews. 2023 Nov 1
Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance.
Darcy K Berry, Nancy Gillis, Eric Padron, Colin Moore, Laura V Barton, Kathleen R Gewandter, Carolyn G Haskins, Todd C Knepper> ;Journal of Genetic Counseling. 2023 Sep 16
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.
Somedeb Ball, Akriti G Jain, Chen Wang, Mohammad O Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E Lancet, Rami S Komrokji...> ;American Journal of Hematology. 2023 Dec 1
1 citations
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
1 citations
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
Mark Gurney, Abhishek A Mangaonkar, Terra Lasho, Christy Finke, Aref Al-Kali, Naseema Gangat, Mithun V Shah, Hassan B Alkhateeb, Ayalew Tefferi, David Sallman, Zhuoer ...> ;Leukemia. 2023 Aug 1
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, Christy Finke, Rhett P Ketterling, Kaaren K Reichard, Rami Komrokji, Eric Padron, Mrinal M Patnaik> ;Leukemia Research. 2023 Aug 1
Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML.
Christopher T Letson, Maria E Balasis, Hannah Newman, Moritz Binder, Alexis Vedder, Fumi Kinose, Markus Ball, Traci Kruer, Ariel Quintana, Terra L Lasho, Christy M Fin...> ;Clinical Cancer Research. 2023 Aug 1
1 citations
Integrative molecular subtypes of acute myeloid leukemia.
Qianxing Mo, Seongseok Yun, David A Sallman, Nicole D Vincelette, Guang Peng, Ling Zhang, Jeffrey E Lancet, Eric Padron> ;Blood Cancer Journal. 2023 May 8
20 citations
Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.
Najla Al Ali, David A Sallman, Somedeb Ball, Akriti G Jain, Onyee Chan, Sara M Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, Rami S Ko...> ;Leukemia. 2023 Jul 1
3 citations
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study.
Gregory A Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wa...> ;Blood Advances. 2023 Jul 25
2 citations
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes.
Rami S Komrokji, Luis E Aguirre, Najla H Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E Lancet, Eric Padron, David A Sallman> ;Blood Advances. 2023 Jul 25
4 citations
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions.
Amy E DeZern, Johannes B Goll, R Coleman Lindsley, Rafael Bejar, Steffanie H Wilson, Donnie Hebert, Joachim Deeg, Ling Zhang, Steven Gore, Tareq Al Baghdadi, Jaroslaw ...> ;Blood Advances. 2023 Jul 25
6 citations
Oxidized Mitochondrial DNA Engages TLR9 to Activate the NLRP3 Inflammasome in Myelodysplastic Syndromes.
Grace A Ward, Robert P Dalton 3rd, Benjamin S Meyer, Amy F McLemore, Amy L Aldrich, Nghi B Lam, Alexis H Onimus, Nicole D Vincelette, Thu Le Trinh, Xianghong Chen, Ale...> ;International Journal of Molecular Sciences. 2023 Feb 15
2 citations
TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases.
Farah Fleti, Onyee Chan, Amritpal Singh, Maymona G Abdelmagid, Aref Al-Kali, Michelle A Elliott, Kebede H Begna, James M Foran, Talha Badar, Nandita Khera, Najla H Al ...> ;American Journal of Hematology. 2023 Apr 1
2 citations
Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.
Yumeng Zhang, Lynn Nguyen, Chuanyi M Lu, Endi Wang, Marietya I S Lauw, Somedeb Ball, Ning Dong, Lynn Moscinski, Onyee Chan, Seongseok Yun, David Sallman, Lubomir Sokol...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Mar 1
1 citations
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
Somedeb Ball, Akriti G Jain, Najla Al Ali, Sara M Tinsley, Onyee Chan, Andrew T Kuykendall, Kendra Sweet, Jeffrey E Lancet, David A Sallman, Mohammad Omar Hussaini, Er...> ;Leukemia Research. 2023 Jan 1
1 citations
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms.
Mrinal M Patnaik, Amer M Zeidan, Eric Padron, Uwe Platzbecker, David A Sallman, Amy E DeZern, Rafael Bejar, Mikkael Sekeres, Justin Taylor, Richard F Little, Jan P Bew...> ;Leukemia. 2022 Dec 1
10 citations
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome.
Rami S Komrokji, Avani M Singh, Najla Al Ali, Onyee Chan, Eric Padron, Kendra Sweet, Andrew Kuykendall, Jeffrey E Lancet, David A Sallman> ;Blood Cancer Journal. 2022 Nov 4
Molecular characteristics and outcomes in Hispanic and non-Hispanic patients with acute myeloid leukemia.
Terrence Bradley, Deukwoo Kwon, Jorge Monge, Mikkael Sekeres, Namrata Chandhok, Amber Thomassen, Ronan Swords, Eric Padron, Jeff Lancet, Chetasi Talati, Justin Watts> ;Ejhaem. 2022 Nov 1
Join now to see all

Journal Articles

Downregulating Notch Counteracts KrasG12D-Induced ERK Activation and Oxidative Phosphorylation in Myeloproliferative Neoplasm
Erik A Ranheim, David Yang, Warren S Pear, Lan Zhou, Mignon Loh, Eric Padron, Elliot Stieglitz, Nature

Abstracts/Posters

Oncogenic Mechanisms of CBL E3 Ubiquitin Ligase Mutations in Myeloid Malignancies
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1 Study of Lenzilumab, a humaneered recombinant Anti_Human Granulocyte-Macrophage Colony- Stimulating Factor (anti-hGM-CSF) Antibody, for Chronic Myelomonocyti...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
RUNX1 Mutation Is Associated with Poor Outcome in Patients with Acute Myeloid Leukemia Receiving Allogeneic Stem Cell Transplantation
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Abnl Marro: An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Bromodomain and Extra Terminal Domain (BET) Inhibitors Sensitize Chronic Myelomonocytic Leukemia (CMML) to PIM Inhibition Via Downregulation of Mir-33a
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Geno-Clinical Model for the Diagnosis of Bone Marrow Myeloid Neoplasms
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All-Trans retinoic Acid (ATRA) through the T...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Overview of Primary and Secondary Myelofibrosis in Young Adults: Genomic Characteristics, Treatment Strategies and Outcomes
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 2 Results of APR-246 and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient Derived Xenografts (PDX) Recapitulate Ruxolitinib Clinical Trial Responses and Identify a Novel Combination Therapy for Chronic Myelomonocytic Leukemia (CMML)
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (_60 Years Old) with Ac...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Timing for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Chronic Myelomonocytic Leukemia (CMML): A Joint Study from the International MDS/MPN Working Gr...
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome
Eric Padron, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Clonal Suppression of TP53 Mutant MDS and Oligoblastic AML with Hypomethylating Agent Therapy Improves Overall Survival
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
SNP-Array Genome Wide Association Study Meta-Analysis Identifies Innate Immune Susceptibility Loci Associated with Non-Del(5q) Myelodysplastic Syndromes Predisposition
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Increased Frequency of IDH1/2 Mutations in Extramedullary Acute Myeloid Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

Blood Mutations Could Contaminate Genetic Analyses of TumorsJune 4th, 2018
Shop TalkJanuary 25th, 2017
JAK2 Inhibitor Ruxolitinib Has Promising Efficacy in CMML PatientsFebruary 12th, 2016

Hospital Affiliations

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment